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Interleukin‐4 and interleukin‐13 evoke scratching behaviour in 
mice
Abstract
Persistent	 and	 relapsing	 itch	 commonly	manifests	 in	 inflammatory	
skin	 disorders	 such	 as	 atopic	 dermatitis	 (AD).	 AD	 pathogenesis	 is	
driven	by	interleukin‐4	(IL‐4)	and	interleukin‐13	(IL‐13).	Dupilumab,	
a	monoclonal	antibody	blocking	the	action	of	 IL‐4	and	IL‐13	effec‐
tively	reduces	the	symptoms	of	AD	and	itch.	Little	is	known	whether	
IL‐4	 and	 IL‐13	 directly	 contribute	 to	 itch	 transduction.	 A	 recently	
published	study	 (Oetjen	et	al,	Cell,	2017,	171,	217)	found	 IL‐4	and	
IL‐13	to	directly	activate	itch‐sensory	neurons	in	vitro.	Surprisingly,	
they	found	no	significant	increase	in	scratching	after	intradermally	
injecting	high	doses	 (2.5	ug/ml)	of	 IL‐4	and	IL‐13	 into	mice.	Similar	
experiments	in	our	lab,	however,	suggested	that	both	IL‐4	and	IL‐13	
contribute	 to	 acute	 itch	 in	 vivo.	We	 intradermally	 injected	 lower	
doses	 (1	ug/ml)	of	 IL‐4	and	 IL‐13	 into	mice	and	found	a	significant	
increase	of	scratching	bouts	compared	to	vehicle.	Interestingly,	the	
combined	treatment	of	IL‐4	and	IL‐13	produced	additive	increase	of	
scratching	and	acute	pruritus	at	an	earlier	 time	point	compared	to	
each	cytokine	administered	alone.	 In	summary,	our	study	shows	a	
rapid	and	significant	 increase	of	scratching	after	 intradermal	 injec‐
tion	 of	 IL‐4,	 IL‐13	 or	 combined	 IL‐4/	 IL‐13	 compared	 to	 vehicle	 in	
mice	 5‐10	minutes	 after	 injection.	Our	 data	 suggest	 that	 IL‐4	 and	
IL‐13	alone	and	combined	directly	act	as	potent	acute	pruritogens	
on	sensory	nerves.	This	 finding	expands	our	understanding	of	 cy‐
tokines	as	pruritogens,	how	targeted	anticytokine	medications	act	in	
AD,	and	about	neuroimmune	communication	in	the	skin.
1  | BACKGROUND
Molecular	 cross‐talk	 between	 the	 immune	 system	 and	 the	 ner‐
vous	system	elicits	evolutionary	responses	such	as	itch	(pruritus)	to	
protect	 the	 host	 from	potential	 pathogens.[1,2]	 This	 neuroimmune,	
physiological	 response	 serves	 notably	 to	 remove	 pathogens	 from	
the	skin.[1]	Pruritus	can	also	be	associated	with	inflammatory	disor‐
ders	such	as	atopic	dermatitis	(AD).[3]	Indeed,	AD	is	a	common	skin	
disease	in	which	IL‐4	and	IL‐13	are	key	players	in	inflammation	and	
neuroimmune	dysfunction.[4]	There	 is	 a	growing	body	of	evidence	
to	show	that	IL‐4	and	IL‐13	are	sensible	targets	for	AD	therapy.[5,6] 
In	 March	 2017,	 the	 US	 Food	 and	 Drug	 Administration	 (FDA)	 ap‐
proved	 a	 human	 anti‐interleukin‐4	 receptor	 alpha	 (IL‐4Rα)	 mono‐
clonal	 antibody	 known	 as	 Dupilumab/Dupixent	 for	 the	 treatment	
of	moderate‐to‐severe	AD.[7]	Dupilumab	targets	the	IL‐4Rα	subunit	
of	 IL‐4	 type	 I	and	 IL‐13	type	 II	 specific	 receptor	complexes.[8]	This	
leads	to	inhibition	of	the	JAK‐STAT	signalling	pathway	known	to	par‐
ticipate	 in	 AD	 pathophysiology.[9]	 After	 subcutaneous	 injection	 of	
Dupilumab	once	a	week	for	12	weeks,	AD	symptoms	were	reduced	
by	 approximately	 50%,	 including	 pruritus	 by	 55.7%[10]	 suggesting	
that	inhibition	of	IL‐4	type	I	signalling	plays	a	role	in	the	reduction	
of	pruritus.	Little	is	known	however	about	whether	IL‐4	or	IL‐13	di‐
rectly	contributes	to	pruritus.
2  | QUESTIONS ADDRESSED
Recently,	Oetjen	et	al[11]	found	that	both	IL‐4	and	IL‐13	are	capable	of	
directly	activating	itch	sensory	neurons	in	vitro.	Thus,	the	authors	in‐
tradermally	injected	wild‐type	mice	with	these	cytokines	and	quan‐
tified	scratching	behaviour.	Interestingly,	the	results	were	contrary	
to	the	researchers’	hypothesis;	 “Based	on	our	 findings	that	 type	2	
cytokines	directly	 activate	 itch	 sensory	neurons,	we	hypothesized	
that	 intradermal	 (i.d.)	administration	of	 IL‐4	and	IL‐13	would	evoke	
acute	itch.	Surprisingly,	in	contrast	to	IL‐31,	high	doses	of	either	IL‐4	
or	IL‐13	did	not	elicit	acute	itch”.[11]	Similar	experiments	in	our	labo‐
ratory,	however,	have	suggested	that	these	cytokines	do	contribute	
to	acute	itch	in	vivo.
3  | E XPERIMENTAL DESIGN
Ten	ul	of	recombinant	mouse	(rm)	IL‐4	(1	µg),	IL‐13	(1	µg)	alone	or	in	
combination,	histamine	(50	µg)	or	vehicle	(0.1%	BSA	in	PBS)	was	in‐
tradermally	injected,	into	the	right	cheek	of	wild‐type	C57/Bl6	mice	
(male,	aged	12	weeks,	n	=	9/group).	Mice	were	video‐recorded	im‐
mediately	after	injection	for	30	minutes.	Scratching	behaviour	was	
measured	as	“bouts”	in	5	minutes	time	bins	for	30	minutes.	One	bout	
of	scratching	was	defined	as	beginning	when	the	hind	paw	was	lifted	
from	the	floor	to	the	right	cheek	and	ending	when	it	returned	to	the	
floor	or	to	the	mouth.[12]
4  | RESULTS
Scratching	 behaviour	 analysis	 was	 carried	 out	 in	 a	 blinded	 fash‐
ion.	 After	 injection	 of	 rmIL‐4,	 there	 was	 a	 significant	 increase	 of	
scratching	 bouts	 compared	with	 vehicle	 and	 an	 overall	 significant	
effect	of	treatment	(P	<	 .0001)	(Figure	1A).	rmIL‐13	also	induced	a	
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significant	 increase	of	scratching	compared	with	vehicle	 (P	<	 .001)	
(Figure	1B).	After	injection	of	the	combination	treatment	rmIL‐4	and	
rmIL‐13,	 there	 was	 a	 significant	 increase	 of	 scratching	 compared	
with	vehicle	(P	<	.0001).	Interestingly,	the	combination	treatment	of	
rmIL‐4	and	rmIL‐13	produced	acute	pruritus	at	an	earlier	time	point	
than	 the	 two	treatments	administered	alone	 (Figure	1C).	Two‐way	
ANOVA	 Bonferroni's	 multiple	 comparison	 test	 indicated	 a	 signifi‐
cant	 increase	of	 scratching	bouts	 in	mice	 i.d.	 injected	with	 rmIL‐4	
at	10	minutes	(P	<	.001)	and	15	minutes	(P	<	.01),	rmIL‐13	at	10	min‐
utes	 (P	<	 .05)	and	rmIL‐4	and	rmIL‐13	 in	combination	at	5	minutes	
(P	<	.0001)	and	10	minutes	(P	<	.0001).	The	combined	activation	of	
IL‐4	 type	 I	 and	 IL‐13	 type	 II	 specific	 receptor	complexes	could	ac‐
count	 for	 the	marked	 increase	 in	 acute	 pruritus.	 rmIL‐4	 showed	 a	
similar	 scratching	 behaviour	 profile	 to	 the	 positive	 control	 group,	
histamine	(Figure	2).
5  | CONCLUSIONS
Our	 results	 show	 that	 IL‐4	 and	 IL‐13	 produce	 a	 direct,	 acute	 pru‐
ritic	 effect	 immediately	 after	 intradermal	 injection	 in	 mice.	 Our	
data	show	comparable	direct	acute	effects	of	 IL‐4	and	 ‐13,	as	ob‐
served	for	IL‐31	which	is	considered	as	a	direct	acute	pruritogen	in	
F I G U R E  1   IL‐4	and	IL‐13	Induce	Acute	Scratching	Behaviour	in	Mice.	Number	of	scratching	bouts	over	the	time	after	injection	of	
rmIL‐4	alone	(A),	IL‐13	alone	(B),	IL‐4	and	IL‐13	(C)	and	histamine	(D).	Statistical	significance	was	found	at	10	min	(P	<	.001)	and	15	min	
(P	<	.01)	(A),	10	min	(P	<	.05)	(B),	5	min	(P	<	.0001)	and	10	min	(P	<	.0001)	(C),	5	min	(P	<	.05)	and	10	min	(P	<	.001)	(D).	Data	in	figures	
represent	mean	±	standard	error	of	the	mean	(SEM).	Statistical	significance	was	determined	by	two‐way	ANOVA	with	Bonferroni's	multiple	
comparison	test.	Statistical	analyses	were	performed	using	Prism	7	(GraphPad	Software).	Two‐way	ANOVA	significance	of	treatment	
is	labelled	as:	****P	<	.0001	and	***P	<	.001,	and	Bonferroni's	multiple	comparison	test	significance	of	time	is	labelled	as:	****P	<	.0001,	
***P	<	.001,	**P	<	.01	and	*P	<	.05.	n	=	9/group
(A) (B)
(C) (D)
F I G U R E  2  Low	Dose	of	IL‐4	and	IL‐13	Induces	Acute	Pruritus	
in	Mice.	Number	of	scratching	bouts	measured	in	response	to	
intradermal	(i.d.)	cheek	injection	of	vehicle	(0.1%	BSA	in	PBS,	
10	mL),	rmIL‐4,	rmIL‐13,	rmIL‐4	and	rmIL‐13	in	combination	(all	
1	µg/10	µL)	or	histamine	(50	µg/10	µL).	Data	in	figures	represent	
mean	±	standard	error	of	the	mean	(SEM).	Statistical	significance	
was	determined	by	unpaired	Student's	t	test	with	Mann‐Whitney	U 
test.	Statistical	analyses	were	performed	using	Prism	7	(GraphPad	
Software).	Significance	is	labelled	as:	***P	<	.001,	**P < .01 and 
*P	<	.05.	n	=	9/group
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mice.[13]	The	observation	of	a	direct	and	acute	effect	 is	supported	
by	expression	of	IL‐4	and	IL‐13	receptors	on	sensory	neurons	(dorsal	
root	ganglion	neurons	(DRG)	and	trigeminal	ganglia)	in	both	mice	and	
humans[11]	and	calcium‐imaging	 trace	studies	where	 IL‐4	and	 IL‐13	
receptor‐positive	mouse	DRG	directly	and	rapidly	release	Ca2+ in re‐
sponse	to	IL‐4	or	IL‐13	stimulation.[11]	However,	our	findings	in	parts	
are	in	contradiction	to	results	obtained	by	Oetjen	et	al[11]	where	IL‐4	
is	described	as	a	chronic	itch	mediator	in	mice	and	humans	without	
acute	pruritic	effects.	A	number	of	hypotheses	could	explain	these	
differences.	First,	the	vehicle	group	in	Oetjen's	work[11]	showed	an	
unexpected	high	number	of	 scratching	bouts	 (approx.	25	bouts	 in	
30	minutes)	similar	to	treatment	groups.	As	a	result,	their	study	finds	
no	 significant	 difference	 of	 scratching	 between	 vehicle	 and	 treat‐
ment.	 Second,	 a	 possible	 explanation	 for	 disparity	 could	 be	 that	
Oetjen	 et	 al[11]	 used	 2.5	 µg	 rmIL‐4	 and	 2.5	 µg	 rmIL‐13	 treatment	
concentrations.	 Maintaining	 equilibrium,	 higher	 concentrations	 in	
healthy	mice	could	stimulate	negative	feedback	regulation.	Negative	
feedback	 dysregulation	 of	 the	 JAK‐STAT	 pathway	 has	 been	 impli‐
cated	in	inflammatory	diseases.[14]	Suppressor	of	cytokine	signalling	
proteins	 (SOCS)	 is	 involved	 in	 the	 negative	 regulation	 of	 cytokine	
signalling.[15]	Suppressor	of	cytokine	signalling	1	 (SOCS1)	and	sup‐
pressor	of	cytokine	signalling	5	(SOCS5)	have	negative	feedback	ac‐
tivity	on	the	JAK‐STAT	pathway	of	IL‐4	signalling.[16]	Also,	IL‐13Rα2 
is	known	to	employ	a	negative	feedback	system	by	blocking	the	sig‐
nalling	of	IL‐4	and	IL‐13.[17‒19]	In	healthy	wild‐type	mice,	it	is	possible	
that	higher	concentrations	may	be	saturating	IL‐4	and	IL‐13	recep‐
tors,	 stimulating	 the	 expression	 of	 SOCS1,	 SOCS5	 and	 IL‐13Rα2,	
inhibiting	 JAK‐STAT	 signalling	of	 IL‐4	 type	 I	 and	 type	 II	 receptors,	
blocking	 the	 activation	 of	 sensory	 neurons	 and	 in	 turn,	 produc‐
ing	a	 lower	scratch	response	compared	with	lower	concentrations.	
Interestingly,	 the	 combined	 treatment	 of	 IL‐4	 and	 IL‐13	 produced	
increased	 scratching	 behaviour	 compared	 with	 treatment	 alone.	
Transgenic	mice	overexpressing	IL‐13	produce	similar	pruritic	effects	
and	have	increased	levels	of	IL‐4	and	IL‐13	in	pruritic	lesions.[20]	IL‐4	
and	IL‐13	are	also	found	to	be	upregulated	in	the	pruritic	AD	lesions	
of	canines[21]	and	also	humans.[22]	It	is	possible	that	combined	activa‐
tion	of	IL‐4	and	IL‐13	receptors	on	itch	sensory	neurons	produce	an	
amplified	pruritic	response	compared	with	activation	alone.
Whether	IL‐4	and	IL‐13	recapitulate	the	acute	pruritic	effects	in	
humans	in	clear	distinction	to	the	pruritic	effects	of	IL‐31	which	acts	
as	 an	acute	pruritogen	 in	mice[11,13]	 and	a	 late	onset	pruritogen	 in	
humans[23]	needs	to	be	addressed	in	detailed	future	studies.
In	summary,	our	study	shows	a	significant	increase	of	scratching	
after	intradermal	injection	of	rmIL‐4,	rmIL‐13	or	rmIL‐4	and	rmIL‐13	in	
combination	compared	with	vehicle	in	mice	after	5‐10	minutes.	Our	
data	suggest	that	IL‐4	and	IL‐13	act	as	acute	(immediate)	pruritogens.	
To	support	these	results,	it	would	be	interesting	to	further	examine	
the	expression	of	SOCS	proteins	 in	response	to	IL‐4	and	IL‐13	in	a	
dose‐dependent	manner	and	using	genetically	altered	IL‐4	and	IL‐13	
mice.	Underpinning	the	molecular	pruritic	profile	would	complement	
and	more	clearly	elucidate	the	role	of	IL‐4	and	IL‐13	in	acute	pruri‐
tus.	Thus,	IL‐4	and	IL‐13	directly	induce	scratching	behaviour	in	mice	
independently	 and	 exert	 an	 additional	 effect	when	 applied	 simul‐
taneously	 thereby	 being	 direct	 targets	 for	 itch	 therapy.	 Clarifying	
the	role	of	cytokines	directly	on	nerves	 is	 important	to	better	un‐
derstand	their	role	in	human	disease	and	to	interpret	the	effects	of	
anti‐cytokine	therapies	with	respect	to	blocking	inflammation	and/
or	pruritus,	respectively.
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